Best Practice & Research Clinical Rheumatology
Volume 24, Issue 4 , Pages 541-552 , August 2010

Prospects for gene therapy in inflammatory arthritis

  • Christian Jorgensen, MD, PhD (Professor, Head of clinical department and of inserm unit U 844)

      Affiliations

    • Inserm, U844, Montpellier, F-34091 France
    • Université MONTPELLIER 1, UFR de Médecine, Montpellier, F-34000 France
    • Service d'immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, F-34295 France
    • Corresponding Author InformationCorresponding author. Inserm U844, CHU Saint Eloi, Bâtiment INM, 80 avenue Augustin Fliche Montpellier F-34295, France. Tel.: +33 4 99 63 60 26; Fax: +33 4 99 63 60 20.
    • ,
  • Florence Apparailly, PhD (Senior Researcher CR1 inserm)

      Affiliations

    • Inserm, U844, Montpellier, F-34091 France
    • Université MONTPELLIER 1, UFR de Médecine, Montpellier, F-34000 France
    • Service d'immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, F-34295 France

References 

  1. Gabriel SE. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis?. Arthritis and Rheumatism. 2008;58:637–640
  2. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–2285
  3. Bessis N, Chiocchia G, Kollias G, et al. Modulation of pro-inflammatory cytokine production in tumour necrosis factor-alpha (TNF-alpha)-transgenic mice by treatment with cells engineered to secrete IL-4, IL-10 or IL-13. Clinical and Experimental Immunology. 1998;111:391–396
  4. Kim SH, Kim S, Evans CH, et al. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. Journal of Immunology. 2001;166:3499–3505
  5. Kim SH, Kim S, Oligino TJ, et al. Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL. Molecular Therapy. 2002;6:584–590
  6. Morita Y, Yang J, Gupta R, et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. The Journal of Clinical Investigation. 2001;107:1275–1284
  7. Annenkov A, Chernajovsky Y. Engineering mouse T lymphocytes specific to type II collagen by transduction with a chimeric receptor consisting of a single chain Fv and TCR zeta. Gene Therapy. 2000;7:714–722
  8. Evans CH, Ghivizzani SC, Robbins PD. Gene therapy for arthritis: what next?. Arthritis and Rheumatism. 2006;54:1714–1729
  9. Ghivizzani SC, Lechman ER, Kang R, et al. Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proceedings of the National Academy of Sciences of The United States of America. 1998;95:4613–4618
  10. Kim SH, Lechman ER, Kim S, et al. Ex vivo gene delivery of IL-1Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis. Molecular Therapy. 2002;6:591–600
  11. Lechman ER, Keravala A, Nash J, et al. The contralateral effect conferred by intra-articular adenovirus-mediated gene transfer of viral IL-10 is specific to the immunizing antigen. Gene Therapy. 2003;10:2029–2035
  12. Mir LM. Therapeutic perspectives of in vivo cell electropermeabilization. Bioelectrochemistry. 2000;53:1–10
  13. Mir LM, Bureau MF, Gehl J, et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proceedings of the National Academy of Sciences of The United States of America. 1999;96:4262–4267
  14. Bloquel C, Bessis N, Boissier MC, et al. Gene therapy of collagen-induced arthritis by electrotransfer of human tumor necrosis factor-alpha soluble receptor I variants. Human Gene Therapy. 2004;15:189–201
  15. Bloquel C, Denys A, Boissier MC, et al. Intra-articular electrotransfer of plasmid encoding soluble TNF receptor variants in normal and arthritic mice. The Journal of Gene Medicine. 2007;9:986–993
  16. Kim JM, Ho SH, Hahn W, et al. Electro-gene therapy of collagen-induced arthritis by using an expression plasmid for the soluble p75 tumor necrosis factor receptor-Fc fusion protein. Gene Therapy. 2003;10:1216–1224
  17. Perez N, Plence P, Millet V, et al. Tetracycline transcriptional silencer tightly controls transgene expression after in vivo intramuscular electrotransfer: application to interleukin 10 therapy in experimental arthritis. Human Gene Therapy. 2002;13:2161–2172
  18. Saidenberg-Kermanac'h N, Bessis N, Deleuze V, et al. Efficacy of interleukin-10 gene electrotransfer into skeletal muscle in mice with collagen-induced arthritis. The Journal of Gene Medicine. 2003;5:164–171
  19. Grossin L, Cournil-Henrionnet C, Mir LM, et al. Direct gene transfer into rat articular cartilage by in vivo electroporation. Faseb J. 2003;17:829–835
  20. Ohashi S, Kubo T, Kishida T, et al. Successful genetic transduction in vivo into synovium by means of electroporation. Biochemical and Biophysical Research Communications. 2002;293:1530–1535
  21. Schiffelers RM, Xu J, Storm G, et al. Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. Arthritis and Rheumatism. 2005;52:1314–1318
  22. Inoue A, Takahashi KA, Mazda O, et al. Comparison of anti-rheumatic effects of local RNAi-based therapy in collagen induced arthritis rats using various cytokine genes as molecular targets. Modern Rheumatology. 2008;
  23. Inoue A, Takahashi KA, Mazda O, et al. Electro-transfer of small interfering RNA ameliorated arthritis in rats. Biochemical and Biophysical Research Communications. 2005;336:903–908
  24. Khoury M, Bigey P, Louis-Plence P, et al. A comparative study on intra-articular versus systemic gene electrotransfer in experimental arthritis. The Journal of Gene Medicine. 2006;8:1027–1036
  25. Howard KA, Paludan SR, Behlke MA, et al. Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Molecular Therapy. 2009;17:162–168
  26. Nagata Y, Nakasa T, Mochizuki Y, et al. Induction of apoptosis in the synovium of mice with autoantibody-mediated arthritis by the intra-articular injection of double-stranded MicroRNA-15a. Arthritis and Rheumatism. 2009;60:2677–2683
  27. Byk G, Dubertret C, Escriou V, et al. Synthesis, activity, and structure–activity relationship studies of novel cationic lipids for DNA transfer. Journal of Medicinal Chemistry. 1998;41:229–235
  28. Khoury M, Escriou V, Courties G, et al. Efficient suppression of murine arthritis by combined anti-cytokine small interfering RNA lipoplexes. Arthritis and Rheumatism. 2008;58:2356–2367
  29. Khoury M, Louis-Plence P, Escriou V, et al. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis and Rheumatism. 2006;54:1867–1877
  30. Metselaar JM, van den Berg WB, Holthuysen AE, et al. Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Annals of the Rheumatic Diseases. 2004;63:348–353
  31. Buchschacher GL, Wong-Staal F. Development of lentiviral vectors for gene therapy for human diseases. Blood. 2000;95:2499–2504
  32. Kustikova OS, Baum C, Fehse B. Retroviral integration site analysis in hematopoietic stem cells. Methods in Molecular Biology. 2008;430:255–267
  33. Thrasher AJ, Gaspar HB, Baum C, et al. Gene therapy: X-SCID transgene leukaemogenicity. Nature. 2006;443:E5–E6discussion E6–7
  34. Jorgensen C, Demoly P, Noel D, et al. Gene transfer to human rheumatoid synovial tissue engrafted in SCID mice. The Journal of Rheumatology. 1997;24:2076–2079[see comments]
  35. Yang S, Wu B, Mayton L, et al. IL-1Ra and vIL-10 gene transfer using retroviral vectors ameliorates particle-associated inflammation in the murine air pouch model. Inflammation Research. 2002;51:342–350
  36. Gouze E, Pawliuk R, Gouze JN, et al. Lentiviral-mediated gene delivery to synovium: potent intra-articular expression with amplification by inflammation. Molecular Therapy. 2003;7:460–466
  37. Lin YL, Noel D, Mettling C, et al. Feline immunodeficiency virus vectors for efficient transduction of primary human synoviocytes: application to an original model of rheumatoid arthritis. Human Gene Therapy. 2004;15:588–596
  38. Lai Kwan Lam Q, King Hung Ko O, Zheng BJ, et al. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proceedings of the National Academy of Sciences of The United States of America. 2008;105:14993–14998
  39. Kremer EJ, Boutin S, Chillon M, et al. Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. Journal of virology. 2000;74:505–512
  40. Seshidhar Reddy P, Ganesh S, Limbach MP, et al. Development of adenovirus serotype 35 as a gene transfer vector. Virology. 2003;311:384–393
  41. Toh ML, Hong SS, van de Loo F, et al. Enhancement of adenovirus-mediated gene delivery to rheumatoid arthritis synoviocytes and synovium by fiber modifications: role of arginine-glycine-aspartic acid (RGD)- and non-RGD-binding integrins. Journal of Immunology. 2005;175:7687–7698
  42. Braz J, Beaufour C, Coutaux A, et al. Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. The Journal of Neuroscience. 2001;21:7881–7888
  43. Evans C, Goins WF, Schmidt MC, et al. Progress in development of herpes simplex virus gene vectors for treatment of rheumatoid arthritis. Advanced Drug Delivery Reviews. 1997;27:41–57
  44. Oligino T, Ghivizzani S, Wolfe D, et al. Intra-articular delivery of a herpes simplex virus IL-1Ra gene vector reduces inflammation in a rabbit model of arthritis. Gene Therapy. 1999;6:1713–1720
  45. Grieger JC, Choi VW, Samulski RJ. Production and characterization of adeno-associated viral vectors. Nature Protocols. 2006;1:1412–1428
  46. Coura Rdos S, Nardi NB. The state of the art of adeno-associated virus-based vectors in gene therapy. Virology Journal. 2007;4:99
  47. Grimm D, Zhou S, Nakai H, et al. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood. 2003;102:2412–2419
  48. Rabinowitz JE, Rolling F, Li C, et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. Journal of virology. 2002;76:791–801
  49. Arruda VR, Fields PA, Milner R, et al. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Molecular Therapy. 2001;4:586–592
  50. Flotte TR. Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Therapy. 2004;11:805–810
  51. Janson C, McPhee S, Bilaniuk L, et al. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Human Gene Therapy. 2002;13:1391–1412
  52. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nature Genetics. 2000;24:257–261
  53. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nature Medicine. 2006;12:342–347
  54. Wang J, Xie J, Lu H, et al. Existence of transient functional double-stranded DNA intermediates during recombinant AAV transduction. Proceedings of the National Academy of Sciences of The United States of America. 2007;104:13104–13109
  55. Arai Y, Kubo T, Fushiki S, et al. Gene delivery to human chondrocytes by an adeno associated virus vector. The Journal of Rheumatology. 2000;27:979–982
  56. Goater J, Muller R, Kollias G, et al. Empirical advantages of adeno associated viral vectors in vivo gene therapy for arthritis. The Journal of Rheumatology. 2000;27:983–989
  57. Madry H, Cucchiarini M, Terwilliger EF, et al. Recombinant adeno-associated virus vectors efficiently and persistently transduce chondrocytes in normal and osteoarthritic human articular cartilage. Human Gene Therapy. 2003;14:393–402
  58. Veron P, Allo V, Riviere C, et al. Major subsets of human dendritic cells are efficiently transduced by self-complementary adeno-associated virus vectors 1 and 2. Journal of virology. 2007;81:5385–5394
  59. Apparailly F, Millet V, Noel D, et al. Tetracycline-inducible interleukin-10 gene transfer mediated by an adeno-associated virus: application to experimental arthritis. Human Gene Therapy. 2002;13:1179–1188
  60. Cottard V, Mulleman D, Bouille P, et al. Adeno-associated virus-mediated delivery of IL-4 prevents collagen-induced arthritis. Gene Therapy. 2000;7:1930–1939
  61. Pan RY, Chen SL, Xiao X, et al. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis and Rheumatism. 2000;43:289–297
  62. Watanabe S, Imagawa T, Boivin GP, et al. Adeno-associated virus mediates long-term gene transfer and delivery of chondroprotective IL-4 to murine synovium. Molecular Therapy. 2000;2:147–152
  63. Zhang HG, Huang N, Liu D, et al. Gene therapy that inhibits nuclear translocation of nuclear factor kappaB results in tumor necrosis factor alpha-induced apoptosis of human synovial fibroblasts. Arthritis and Rheumatism. 2000;43:1094–1105
  64. Pan RY, Xiao X, Chen SL, et al. Disease-inducible transgene expression from a recombinant adeno-associated virus vector in a rat arthritis model. Journal of virology. 1999;73:3410–3417
  65. Adriaansen J, Tas SW, Klarenbeek PL, et al. Enhanced gene transfer to arthritic joints using adeno-associated virus type 5: implications for intra-articular gene therapy. Annals of the Rheumatic Diseases. 2005;64:1677–1684
  66. Apparailly F, Khoury M, Vervoordeldonk MJ, et al. Adeno-associated virus pseudotype 5 vector improves gene transfer in arthritic joints. Human Gene Therapy. 2005;16:426–434
  67. Evans CH, Gouze E, Gouze JN, et al. Gene therapeutic approaches-transfer in vivo. Advanced Drug Delivery Reviews. 2006;58:243–258
  68. Adriaansen J, Khoury M, de Cortie CJ, et al. Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent. Annals of the Rheumatic Diseases. 2007;
  69. Khoury M, Adriaansen J, Vervoordeldonk MJ, et al. Inflammation-inducible anti-TNF gene expression mediated by intra-articular injection of serotype 5 adeno-associated virus reduces arthritis. The Journal of Gene Medicine. 2007;
  70. Khoury M, Courties G, Fabre S, Bouffi C, Seemayer CA, Vervoordeldonk MJ, et al. Adeno-Associated Virus Type 5–mediated intra-articular administration of tumor necrosis factor small interfering RNA Improves collagen-induced arthritis. Arthritis and Rheumatism. 2010;62(3):765–770
  71. DiPrimio N, Asokan A, Govindasamy L, et al. Surface loop dynamics in adeno-associated virus capsid assembly. Journal of Virology. 2008;82:5178–5189
  72. Li W, Asokan A, Wu Z, et al. Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Molecular Therapy. 2008;16:1252–1260
  73. Srivastava A. Adeno-associated virus-mediated gene transfer. Journal of Cellular Biochemistry. 2008;
  74. Evans CH, Robbins PD, Ghivizzani SC, et al. Gene transfer to human joints: progress toward a gene therapy of arthritis. Proceedings of the National Academy of Sciences of The United States of America. 2005;102:8698–8703
  75. Williams DA. RAC reviews serious adverse event associated with AAV therapy trial. Molecular Therapy. 2007;15:2053–2054
  76. Adriaansen J, Fallaux FJ, de Cortie CJ, et al. Local delivery of beta interferon using an adeno-associated virus type 5 effectively inhibits adjuvant arthritis in rats. The Journal of General Virology. 2007;88:1717–1721
  77. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nature Reviews. Immunology. 2007;7:429–442
  78. Smolen JS, Redlich K, Zwerina J, et al. Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects. Clinical Reviews in Allergy & Immunology. 2005;28:239–248
  79. Joosten LA, Helsen MM, van de Loo FA, et al. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNF-alpha, anti-IL-1alpha/beta and IL-1Ra. Arthritis and Rheumatism. 2008;58:S110–S122
  80. van de Loo FA, Joosten LA, van Lent PL, et al. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis and Rheumatism. 1995;38:164–172
  81. Lewthwaite J, Blake S, Hardingham T, et al. Role of TNF alpha in the induction of antigen induced arthritis in the rabbit and the anti-arthritic effect of species-specific TNF alpha neutralising monoclonal antibodies. Annals of the Rheumatic Diseases. 1995;54:366–374
  82. Mountz JD, Zhang HG. Regulation of apoptosis of synovial fibroblasts. Current Directions in Autoimmunity. 2001;3:216–239
  83. Yao Q, Seol DW, Mi Z, et al. Intra-articular injection of recombinant TRAIL induces synovial apoptosis and reduces inflammation in a rabbit knee model of arthritis. Arthritis Research & Therapy. 2006;8:R16
  84. Yao Q, Wang S, Glorioso JC, et al. Gene transfer of p53 to arthritic joints stimulates synovial apoptosis and inhibits inflammation. Molecular Therapy. 2001;3:901–910
  85. Kobayashi T, Okamoto K, Kobata T, et al. Novel gene therapy for rheumatoid arthritis by FADD gene transfer: induction of apoptosis of rheumatoid synoviocytes but not chondrocytes. Gene Therapy. 2000;7:527–533
  86. Wang CR, Shiau AL, Chen SY, et al. Amelioration of collagen-induced arthritis in rats by adenovirus-mediated PTEN gene transfer. Arthritis and Rheumatism. 2008;58:1650–1656
  87. Goossens PH, Schouten GJ, t Hart BA, et al. Feasibility of adenovirus-mediated nonsurgical synovectomy in collagen-induced arthritis-affected rhesus monkeys. Human Gene Therap. 1999;10:1139–1149
  88. Sant SM, Suarez TM, Moalli MR, et al. Molecular lysis of synovial lining cells by in vivo herpes simplex virus-thymidine kinase gene transfer. Human Gene Therapy. 1998;9:2735–2743
  89. Colville-Nash PR, Scott DL. Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Annals of the Rheumatic Diseases. 1992;51:919–925
  90. Chen Y, Donnelly E, Kobayashi H, et al. Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction. Arthritis and Rheumatism. 2005;52:1585–1594
  91. Gerlag DM, Borges E, Tak PP, et al. Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature. Arthritis Research. 2001;3:357–361
  92. Afuwape AO, Feldmann M, Paleolog EM. Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis. Gene Therapy. 2003;10:1950–1960
  93. Kim JM, Ho SH, Park EJ, et al. Angiostatin gene transfer as an effective treatment strategy in murine collagen-induced arthritis. Arthritis and Rheumatism. 2002;46:793–801
  94. Jou IM, Shiau AL, Chen SY, et al. Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis. Arthritis and Rheumatism. 2005;52:339–344
  95. Park YW, Kang YM, Butterfield J, et al. Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis. The American Journal of Pathology. 2004;165:2087–2098
  96. Apparailly F, Bouquet C, Millet V, et al. Adenovirus-mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis. Gene Therapy. 2002;9:192–200
  97. Rutkauskaite E, Zacharias W, Schedel J, et al. Ribozymes that inhibit the production of matrix metalloproteinase 1 reduce the invasiveness of rheumatoid arthritis synovial fibroblasts. Arthritis and Rheumatism. 2004;50:1448–1456
  98. Rutkauskaite E, Volkmer D, Shigeyama Y, et al. Retroviral gene transfer of an antisense construct against membrane type 1 matrix metalloproteinase reduces the invasiveness of rheumatoid arthritis synovial fibroblasts. Arthritis and Rheumatism. 2005;52:2010–2014
  99. Meinecke I, Rutkauskaite E, Cinski A, et al. Gene transfer to synovial fibroblast: methods and evaluation in the SCID mouse model. Methods in Molecular Medicine. 2007;135:393–412
  100. van der Laan WH, Quax PH, Seemayer CA, et al. Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Therapy. 2003;10:234–242
  101. Apparailly F, Noel D, Millet V, et al. Paradoxical effects of tissue inhibitor of metalloproteinases 1 gene transfer in collagen-induced arthritis. Arthritis and Rheumatism. 2001;44:1444–1454
  102. Jimi E, Ghosh S. Role of nuclear factor-kappaB in the immune system and bone. Immunological Reviews. 2005;208:80–87
  103. Tas SW, Adriaansen J, Hajji N, et al. Amelioration of arthritis by intra-articular dominant negative Ikk beta gene therapy using adeno-associated virus type 5. Human Gene Therapy. 2006;17:821–832
  104. Tak PP, Gerlag DM, Aupperle KR, et al. Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritis and Rheumatism. 2001;44:1897–1907
  105. Tomita T, Takano H, Tomita N, et al. Transcription factor decoy for NFkappaB inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis. Rheumatology (Oxford). 2000;39:749–757
  106. Tomita T, Takeuchi E, Tomita N, et al. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy. Arthritis and Rheumatism. 1999;42:2532–2542
  107. Kubota T, Hoshino M, Aoki K, et al. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor. Arthritis Research & Therapy. 2007;9:R97
  108. Campbell J, Ciesielski CJ, Hunt AE, et al. A novel mechanism for TNF-alpha regulation by p38 MAPK: involvement of NF-kappa B with implications for therapy in rheumatoid arthritis. Journal of Immunology. 2004;173:6928–6937
  109. Simmonds RE, Foxwell BM. Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation. Rheumatology (Oxford). 2008;47:584–590
  110. Lianxu C, Hongti J, Changlong Y. NF-kappaBp65-specific siRNA inhibits expression of genes of COX-2, NOS-2 and MMP-9 in rat IL-1beta-induced and TNF-alpha-induced chondrocytes. Osteoarthritis and Cartilage. 2006;14:367–376
  111. Aikawa Y, Morimoto K, Yamamoto T, et al. Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1. Nature Biotechnology. 2008;26:817–823
  112. Fahmy RG, Waldman A, Zhang G, et al. Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun. Nature Biotechnology. 2006;24:856–863
  113. Agarwal SK, Brenner MB. Role of adhesion molecules in synovial inflammation. Current Opinion in Rheumatology. 2006;18:268–276
  114. Kiener HP, Brenner MB. Building the synovium: cadherin-11 mediates fibroblast-like synoviocyte cell-to-cell adhesion. Arthritis Research & Therapy. 2005;7:49–54
  115. Lee DM, Kiener HP, Agarwal SK, et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science. 2007;315:1006–1010

PII: S1521-6942(10)00011-2

doi: 10.1016/j.berh.2010.02.001

Best Practice & Research Clinical Rheumatology
Volume 24, Issue 4 , Pages 541-552 , August 2010

Article Tools

* Image Usage & Resolution